Trial Profile
Effect of Docosahexenoic Acid (22:6n-3, DHA) Supplementation on Risk Factors for Cardiovascular Disease in Hyperlipidemic Men
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docosahexaenoic acid (Primary)
- Indications Hypertriglyceridaemia
- Focus Biomarker; Therapeutic Use
- 02 Jul 2014 New trial record